Catheter for modified perfusion

Patent Citations (99)

Non-Patent Literature (98)

• Agnelli, et al., “Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated Rabbits,” Thromb. Haemost., 1991; 66(5): 592-597.Applicant
• Ambrosio, et al., “Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury,” Circulation, 1987; 76(4): 906-915.Applicant
• Auchampach, et al., “Anti-ischaemic actions of potassium channel openers in experimental myocardial ischaemia/reperfusion injury in dogs,” Eur. Heart Jour., 1993; 14(Supp. B): 10-15.Applicant
• Auchampach, et al., “Reduction in Myocardial Infarct Size by the New Potassium Channel Opener Bimakalim,” J. Cardiovasc. Pharmacol., 1994; 23(4): 554-561.Applicant
• Auchampach, et al., “Pharmacological Evidence for a Role of ATP-Dependent Potassium Channels in Myocardial Stunning,” Circulation, 1992; 86: 311-319.Applicant
• Axford-Gately, et al., “Myocardial infarct size reduction by single high dose or repeated low dose vitamin E supplementation in rabbits,” Can. J. Cardiol., 1993; 9(1): 94-98.Applicant
• Baines, et al., “Protein Tyrosine Kinase is Downstream of Protein Kinase C for Ischemic Preconditioning's Anti-Infarct Effect in the Rabbit Heart,” J. Mol. Cell Cardiol., 1998; 30: 383-392.Applicant
• Balakirev, et al., “Gradual Changes in Permeability of Inner Mitochondrial Membrane Precede the Mitochondrial Permeability Transition,” Arch. Biochem. Biophys., 1998; 356(1): 46-54.Applicant
• Barta, et al., “Protective Effect of Alpha-tocopherol and L-Ascorbic Acid against the Ischemic-Reperfusion Injury in Patients During Open-heart Surgery,” Bratisl. Lek. Listy, 1991; 92(3-4): 174-183.Applicant
• Buus, et al., “Influence of Nitric Oxide Synthase and Adrenergic Inhibition on Adenosine-Induced Myocardial Hyperemia,” Circulation, 2001; 104(19): 2305-2310.Applicant
• Chen, et al., “Prostacyclin Analogue (OP-2507) Attenuates Hepatic Microcirculatory Derangement, Energy Depletion, and Lipid Peroxidation in a Rat Model of Reperfusion Injury,” J. Surg. Res., 1998; 80(2): 333-338.Applicant
• Chiari, et al., “Isoflurane Protects against Myocardial Infarction during Early Reperfusion by Activation of Phosphatidylinositol-3-Kinase Signal Transduction: Evidence for Anesthetic-induced Postconditioning in Rabbits,” Anesthesiology, 2005;102(1): 102-109.Applicant
• Chiari, et al., “Role of Endothelial Nitric Oxide Synthase as a Trigger and Mediator of Isoflurane-induced Delayed Preconditioning in Rabbit Myocardium,” Anesthesiology, 2005; 103(1): 74-83.Applicant
• Davenpeck, et al., “Inhibition of Endothelial-Derived Nitric Oxide Promotes P-Selectin Expression and Actions in the Rat Microcirculation,” Gastroenterology, 1994; 107: 1050-1058.Applicant
• Downey, J., “Ischemic Preconditioning: Nature's Own Cardioprotective Intervention,” Trends Cardiovasc. Med., 1992; 2: 170-176.Applicant
• Duilio, et al., “Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia,” Am. J. Physiol. Heart Circ. Physiol., 2001; 280: H2649-H2657.Applicant
• Euler, D., “Role of oxygen-derived free radicals in canine reperfusion arrhythmias,” Am. J. Physiol. Heart Circ. Physiol., 1995; 268: H295-H300.Applicant
• Garcia-Dorado, et al., “Bringing preconditioning and postconditioning into focus.” Cardiovasc. Res., 2006; 70: 167-169.Applicant
• Griffiths, et al., “Protection by Cyclosporin A of Ischemia/Reperfusion-Induced Damage in Isolated Rat Hearts,” J. Mol. Cell Cardiol., 1993; 25: 1461-1469.Applicant
• Gross, et al., “Cardioprotective Effects of Nicorandil.” J. Cardiovasc. Pharmacol., 1992; 20 (Suppl 3): S22-S28.Applicant
• Gross, et al., “The ATP-Regulated Potassium Channel in Ischemia-Reperfusion Injury,” Ann. N.Y. Acad. Sci., 1994; 723: 71-81.Applicant
• Grover, et al., “The Protective Effects of Cromakalim and Pinacidil on Reperfusion Function and Infarct Size in Isolated Perfused Rat Hearts and Anesthetized Dogs,” Cardiovasc. Drugs Ther., 1990; 4: 465-474.Applicant
• Gumina, et al., “A New Sodium/Hydrogen Exchange Inhibitor, EMD 85131, Limits Infarct Size in Dogs When Administered Before or After Coronary Artery Occlusion,” J. Pharmacol. Exp. Ther., 1998; 286(1): 175-183.Applicant
• Gunnes, et al., “Improved energy preservation following gentle reperfusion after hypothermic, ischemic cardioplegia in infarcted rat hearts.” Eur. J. of Cardiothorac. Surg., 1987; 1: 139-143.Applicant
• Halkos, et al., “Myocardial Protection With Postconditioning is Not Enhanced by Ischemic Preconditioning,” Ann. Thorac. Surg., 2004; 78(3):961-969.Applicant
• Hausenloy, et al., “Ischemic preconditioning protects by activating prosurvival kinases at reperfusion,” Am. J. Physiol. Heart Circ. Physiol., 2005; 288: H971-H976.Applicant
• Hausenloy, et al., “New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway,” Cardiovasc. Res., 2004; 61(3): 448-460.Applicant
• Hausenloy, et al., “Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?” Cardiovasc. Res., 2002; 55: 534-543.Applicant
• Hirano, et al., “The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats,” Surgery, 2001; 129(5): 595-605.Applicant
• Hoshida, et al., “Nitric Oxide Synthase Protects the Heart against Ischemia-Reperfusion Injury in Rabbits,” J. Pharmacol. Exp. Ther., 1995; 274(1): 413-418.Applicant
• Jackson, et al., “Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels,” Am. J. Physiol., 1993; 264: H238-H243.Applicant
• Jiang, et al., “Postconditioning Reduces Reperfusion Injury by Inhibiting the Tissue Factor-Thrombin Pathway in a Closed-Chest Porcine Model Of Ischemia-Reperfusion,” Scientific Sessions, 2005; Abstract No. 1554.Applicant
• Jiang, et al., “Which ‘survival’ and/or ‘death’ kinases contribute to postconditioning in rabbit heart?,” Journal of Molecular And Cellular Cardiology, 2005; 38: 809-885, Abstract No. 129.Applicant
• Jordan, et al., “The role of neutrophils in myocardial ischemia-reperfusion injury.” Cardiovas. Res., 1999; 43: 860-878.Applicant
• Karmazyn, M., “Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases,” Exp. Opin. Invest. Drugs, 2000; 9(5): 1099-1108.Applicant
• Kato, K., “Haemodynamic and clinical effects of an intravenous potassium channel opener—a review,” Eur. Heart Jour., 1993; 14 (Supp. B): 40-47.Applicant
• Katoh, et al., “Deferoxamine Reduces the Reperfusion Injury in Isolated Neonatal Rabbit Hearts After Hypothermic Preservation,” Surg. Today, Jpn. J. Surg., 1993; 23: 424-429.Applicant
• Kerendi, et al., “Remote postconditioning,” Basic Res. in Cardiol., 2005; 100: 404-412.Applicant
• Kin, et al., “Pharmacological Enhancement of Post-Conditioning (PEP-C) Increases Myocardial Salvage after Acute Myocardial Infarction,” Scientific Sessions, 2005; Abstract No. 1556.Applicant
• Kin, et al., “Neutrophil depletion and oxidant inhibition reduce myocardial apoptosis by inhibiting activation of caspase-3 and up-regulating bcl-2 expression,” Journal of Molecular and Cellular Cardiology, 2005; 38: 809-885, Abstract No. 48.Applicant
• Kin, et al., “Activation of opioid receptors mediates the infarct size reduction by Postconditioning,” Journal of Molecular and Cellular Cardiology, 2005; 38: 809-885, Abstract No. 49.Applicant
• Kin, et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion,” Cardiovasc. Res., 2004; 62: 74-85.Applicant
• Kin, et al., “Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine,” Cardiovascular Res., 2005; 67: 124-133.Applicant
• Kodani, et al., “Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor,” Basic Res. Cardiol., 2001; 96(5): 487-496.Applicant
• Lam, et al., “The Effect of Aurintricarboxylic Acid, an Endonuclease Inhibitor, on Ischemia/Reperfusion Damage in Rat Retina,” Jour. Ocular Pharmacol. Therap., 1995; 11(3): 253-259.Applicant
• Lefer, et al., “Endothelial Dysfunction and Neutrophil Adherence as Critical Events in the Development of Reperfusion Injury,” Agents Actions (Suppl), 1993; 41: 127-135.Applicant
• Linz, et al., “Dose-Dependent Reduction Of Myocardial Infarct Mass In Rabbits by the NHE-1 Inhibitor Cariporide (HOE 642),” Clin. Exp. Hypertens., 1998; 20(7): 733-749.Applicant
• Miura, et al., “Mitochondrial ATP-Sensitive K+ Channels Play a Role in Cardioprotection by Na+- H+ Exchange Inhibition Against Ischemia/Reperfusion Injury,” J. Am. Coll. Cardiol., 2001; 37(3): 957-963.Applicant
• Mizumura, et al., “Bimakalim, an ATP-Sensitive Potassium Channel Opener, Mimics the Effects of Ischemic Preconditioning to Reduce Infarct Size, Adenosine Release, and Neutrophil Function in Dogs,” Circulation, 1995; 92: 1236-1245.Applicant
• Murry, et al., “Editorial Comment: New Insights Into Potential Mechanisms of Ischemic Preconditioning,” Circulation, 1991; 84: 442-445.Applicant
• Murry, et al., “Ischemic Preconditioning Slows Energy Metabolism and Delays Ultrastructural Damage During a Sustained Ischemic Episode,” Circ. Res., 1990; 66: 913-931.Applicant
• Murry, et al., “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium,” Circulation, 1986; 74(5): 1124-1136.Applicant
• Mykytenko, et al., “Long-term inhibition of myocardial infarction by postconditioning during reperfusion,” Basic Res. Cardiol., 2007; 102(1): 90-100.Applicant
• Neely, et al., “A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung,” Amer. J. Physiol., 1995; 268(6): L1036-L1046.Applicant
• Neely, et al., “A1 Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart,” Circulation, 1996; 94(9 Suppl.): II376-II380.Applicant
• Ockaili, et al., “Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits,” Am. J. Physiol. Heart Circ. Physiol., 2002; 283: H1263-H1269.Applicant
• Okamoto, et al., “Perivascular Inflammation After Balloon Angioplasty of Porcine Coronary Arteries,” Circulation, 2001; 104: 2228-2235.Applicant
• Ooiwa, et al., “Examination of Two Small-Molecule Antiperoxidative Agents in a Rabbit Model of Postischemic Myocardial Infarction,” J. Cardiovasc. Pharmacol., 1991; 17(5): 761-767.Applicant
• Piper, et al., “A fresh look at reperfusion injury,” Cardiovasc. Res., 1998; 38: 291-300.Applicant
• Piper, et al., “Cellular Mechanisms of Ischemia-Reperfusion Injury.” Ann. Thorac. Surg., 2003; 75: S644-S648.Applicant
• Piper, et al., “The first minutes of reperfusion: a window of opportunity for cardioprotection,” Cardiovasc. Res., 2004; 61(3): 365-371.Applicant
• Piper, et al., “Prime Causes of Rapid Cardiomyocyte Death During Reperfusion,” Ann. Thorac. Surg., 1999; 68: 1913-1919.Applicant
• Qin, et al., “Acetylcholine but Not Adenosine Triggers Preconditioning by a Pathway Involving Src and P13 Kinases,” Circulation, Suppl. II, 2002; 106(19), Abstract No. 1573.Applicant
• Reimer, et al., “Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis,” Am. J. Physiol., 1986; 251: H1306-H1315.Applicant
• Reimer, et al., “The ‘Wavefront Phenomenon’ of Ischemic Cell Death—1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs,” Circulation, 1977; 56(5): 786-794.Applicant
• Reimer, et al., “The ‘Wavefront Phenomenon’ of Myocardial Ischemic Cell Death—II. Transmural Progression of Necrosis within the Framework of Ischemic Bed Size (Myocardium at Risk) and Collateral Flow,” Lab Invest., 1979; 40(6): 633-644.Applicant
• Rosenbaum, et al., “Pretreatment with Intraventricular Aurintricarboxylic Acid Decreases Infarct Size by Inhibiting Apoptosis following Transient Global Ischemia in Gerbils,” Ann. Neurol., 1998; 43(5): 654-660.Applicant
• Sanz et al., “Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning,” Am. J. Physiol., 2003; 268 (1 Pt 2): H233-41, (Abstract).Applicant
• Sato, et al., “Gradual Reperfusion Reduces Infarct Size and Endothelial Injury but Augments Neutrophil Accumulation.” Ann. Thorac. Surg., 1997; 64: 1099-1107.Applicant
• Schipke, et al., “Postkonditionierung: Ein kurzer Überblick,” Herz, 2006; 31(6): 600-606.Applicant
• Schultz, et al., “Opioids and cardioprotection,” Pharmacol. Ther., 2001; 89(2): 123-137.Applicant
• Staat, et al., “Postconditioning the Human Heart,” Circulation, 2005; 112: 2143-2148.Applicant
• Sun, et al., “Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways,” Apoptosis, 2006; 11(9): 1583-1593.Applicant
• Sun, et al., “Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload,” Am. J. Physiol. Heart Circ. Physiol., 2005; 288(4): H1900-H1908.Applicant
• Thourani, et al., “Nonanticoagulant heparin inhibits NF-κB activation and attenuates myocardial reperfusion injury,” Am. J. Physiol. Heart Circ. Physiol., 2000; 48: H2084-H2093.Applicant
• Vinten-Johansen, J., “Reperfusion Injury: Idle Curiosity or Therapeutic Vector?” Journal of Thrombosis and Thrombolysis, 1997; 4: 59-61.Applicant
• Vinten-Johansen, J., “Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury,” Cardiovasc. Res., 2004; 61: 481-497.Applicant
• Vinten-Johansen, et al., “Controlled coronary hydrodynamics at the time of reperfusion reduces postischemic injury,” Coronary Artery Disease, 1992; 3: 1081-1093.Applicant
• Vinten-Johansen, et al., “Postconditioning—A new link in nature's armor against myocardial ischemia reperfusion injury,” Basic Res. Cardiol., 2005; 100(4): 295-310.Applicant
• Vinten-Johansen, et al., “Postconditioning—A Simple, Clinically Applicable Procedure to Improve Revascularization in Acute Myocardial Infarction,” Circulation, 2005; 112: 2085-2088.Applicant
• Vinten-Johansen, et al., “Myocardial protection in reperfusion with postconditioning,” Expert Rev. Cardiovasc. Ther., 2005; 3(6): 1035-1045.Applicant
• Vinten-Johansen, J., “Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion,” Heart Fail. Rev., 2007; 12(3-4): 235-244.Applicant
• Vinten-Johansen, et al., “Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury,” J. Appl. Physiol., 2007; 103(4): 1441-1448.Applicant
• Vinten-Johansen, et al., “Post-Conditioning Reduces Myocardial Injury by Inhibiting Reactive Oxygen Species During Reperfusion,” Circulation, 2003; 108(Suppl.): IV-219 (Abstract).Applicant
• Weber, et al., “Cardioprotection by Blockade of Src Activity in Models of Acute Myocardial Infarction,” Circulation, Suppl. II, 2002; 106(19), Abstract No. 1574.Applicant
• Yang, et al., “Permanent Reduction in Myocardial Infarct Size by Postconditioning in Patients after Primary Coronary Angioplasty,” Circulation, Suppl. II, 2006; 114(18), Abstract No. 3795.Applicant
• Yang, et al., “Multiple, Brief Coronary Occlusions During Early Reperfusion Protect Rabbit Hearts by Activation of ERK and Production of Nitric Oxide,” Circulation (Suppl), 2003; 108(17), IV-745 (Abstract).Applicant
• Zatta, et al., “Postconditioning reduces infarct size via activation of adenosine A2A and A3 receptor subtypes,” Journal of Molecular and Cellular Cardiology, 2005; 38: 809-885, Abstract No. 4.Applicant
• Zatta, et al., “Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signaling,” Cardiovasc. Res., 2006; 70(2): 315-324.Applicant
• Zeymer, et al., “The Na+/H+ Exchange Inhibitor Eniporide as an Adjunct to Early Reperfusion Therapy for Acute Myocardial Infarction,” J. Am. Coll. Cardiol., 2001; 38(6): 1644-1650.Applicant
• Zhao, et al., “Dynamic Progression of Contractile and Endothelial Dysfunction and Infarct Extension in the Late Phase of Reperfusion,” J. Surg. Res., 2000; 94: 133-144.Applicant
• Zhao, et al., “Postconditioning: Reduction of reperfusion-induced injury,” Cardiovas. Res., 2006; 70: 200-211.Applicant
• Zhao, et al., “Hypoxic Postconditioning Attenuates Cardiomyocyte Apoptosis via Inhibition of JNK and p38 Mitogen-Activated Protein Kinase Pathway,” International Society for Heart Research, J.. Molecular & Cellullar Cardiol., 2005; 38: 870 (Abstract).Applicant
• Zhao, et al., “Reduction in Infarct Size and Preservation of Endothelial Function by Ischemic Postconditioning: Comparison with Ischemic Preconditioning.” Circulation, Suppl. II, 2002; 106(19), Abstract No. 1575.Applicant
• Zhao et al. “Hypoxic Post-Conditioning Reduces Cardiomyocyte Loss by Inhibiting Reactive Oxygen Species-Triggered Mitochondrial Calcium Overload,” Circulation (Suppl.), 2003; 108(17): IV-174 (Abstract).Applicant
• Zhao, et al. “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning,” Am. J. Physiol. Heart Circ. Physiol., 2003; 285: H579-H588.Applicant
• Zhao, et al., “Progressively developed myocardial apoptotic cell death during late phase of reperfusion,” Apoptosis, 2001; 6(4):279-290.Applicant
• Zhao, et al., “Infarct Extension and Dynamic Coronary Endothelial Dysfunction in the Late Reperfusion Phase,” Circulation, Suppl. I, 1998; Abstract No. 4169.Applicant